What is Harbin Pharmaceutical Group Co FCF Yield %?
Harbin Pharmaceutical Group CoSHSE:600664 +0.96%78 FCF Yield % is 7.16 as of Jul. 05, 2026, which is 132% above its 10-year median of 3.08. GuruFocus rates SHSE:600664 with a GF Score™ of 78/100 and a GF Value™ of ¥3.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,004 Drug Manufacturers companies, Harbin Pharmaceutical Group Co ranks better than 82.07% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Harbin Pharmaceutical Group Co's FCF Yield % or its related term are showing as below:
SHSE:600664'
s FCF Yield % Range Over the Past 10 Years
Min: -14.07 Med: 3.08 Max: 18.08
Current: 7.16
During the past 13 years, the highest FCF Yield % of Harbin Pharmaceutical Group Co was 18.08%. The lowest was -14.07%. And the median was 3.08%.
SHSE:600664's FCF Yield % is ranked better than 82.07% of 1004
companies
in the Drug Manufacturers industry
Industry Median: 0.665
vs SHSE:600664: 7.16
Harbin Pharmaceutical Group Co FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Harbin Pharmaceutical Group Co FCF Yield % Related Terms
Harbin Pharmaceutical Group Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harbin Pharmaceutical Group Co FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Harbin Pharmaceutical Group Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co (SHSE:600664) has a FCF Yield % of 7.16 as of Jul. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Harbin Pharmaceutical Group Co and its competitors. This is 132% above median its historical median of 3.08. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #180 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 17.9%.
Is Harbin Pharmaceutical Group Co's FCF Yield % too high?
Harbin Pharmaceutical Group Co's current FCF Yield % of 7.16 is 132% above median its 10-year median of 3.08. The Drug Manufacturers industry median FCF Yield % is 0.67. Harbin Pharmaceutical Group Co's value of 7.16 is 976.7% above this industry median. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #180 out of 1004 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #180 out of 1004 companies for FCF Yield %. This places Harbin Pharmaceutical Group Co in the top 18% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Harbin Pharmaceutical Group Co's value of 7.16 is 976.7% above this benchmark. While the company's 10-year median is 3.08 vs. the industry median of 0.67, Harbin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harbin Pharmaceutical Group Co's current FCF Yield % of 7.16 is 976.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Harbin Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current FCF Yield % is 7.16, which is 132% above median its own 10-year median of 3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥3.14 — trading 10.5% below its estimated fair value. The current FCF Yield % is 7.16, which is 132% above median its 10-year median of 3.08 and 976.7% above the Drug Manufacturers industry median of 0.67. Harbin Pharmaceutical Group Co's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current FCF Yield % is 7.16 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥3.14 is trading 10.5% below its estimated GF Value™ of ¥3.51.
GuruFocus considers Harbin Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600664:
FCF Yield %: 7.16 (132% above median its 10-year median of 3.08)
GF Value™: ¥3.51 vs. price of ¥3.14 (10.5% below fair value)
Industry Position: 976.7% above the Drug Manufacturers median (#180 of 1004)
No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harbin Pharmaceutical Group Co Business Description
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
78GF Score
Get the complete analysis for SHSE:600664
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600664 has been successfully added to your 
